Fewer Than Half of Multisite MMP Patients Reach Remission at All Sites

Fewer than half of patients with multisite mucous membrane pemphigoid (MMP) achieved simultaneous remission across all affected sites, despite strong response rates at individual sites, according to a new study published in JAMA. Persistent oral and ocular disease drove most failures of overall disease control.

The cohort comprised 77 participants, and the disease burden was severe: 68 patients (88%) had involvement of at least one high-risk site — the eyes, larynx, oesophagus or anogenital region. The researchers concluded that MMP behaves in a site-dependent manner and that future studies need standardized multisite remission criteria to capture outcomes accurately.

Which sites dominate the clinical picture?

Oral disease affected 73 of the 77 patients (95%), making it the near-universal presentation. Ocular involvement followed in 51 patients (66%), and nasal disease in 38 (49%). The overlap of oral and ocular involvement in most patients explains why these two sites dictated overall remission status in the analysis.

The investigators emphasized that high response rates at single sites can mask ongoing, functionally significant disease elsewhere — particularly in the eyes, where untreated activity risks permanent structural damage.

How often did remission hold?

Relapse was frequent. Of the 64 patients who achieved complete remission at one or more sites, 28 (44%) subsequently relapsed. The oral mucosa was involved in 18 of those relapsing patients (64%), and ocular disease recurred in 14 (50%). Some patients relapsed at multiple sites simultaneously, complicating retreatment decisions.

That relapse profile reinforces the site-dependent character of the disease: the mucosa that responds first and most reliably is also the one most likely to reactivate.

What did the treatments show?

Treatment responses varied across regimens. Rituximab-based regimens and Janus kinase (JAK) inhibitor therapy were both associated with high rates of improvement. However, the researchers noted that remission rates with rituximab-based regimens in this cohort ran lower than those reported in some previously published MMP cohorts — a discrepancy that warrants cautious interpretation when cross-study comparisons inform therapy selection.

Serious adverse events occurred during the study. These were most frequently reported with cyclophosphamide monotherapy and with JAK inhibitor therapy, tempering the efficacy signal for those approaches.

Why do the findings matter for practice?

The data argue against judging MMP control by the easiest-to-assess site. A patient with a quiet mouth but active ocular disease remains uncontrolled in the terms that matter most, given that 88% of this cohort carried high-risk site involvement and half of relapses involved the eyes.

The authors' call for standardized multisite remission criteria points to the next step for the field: outcome definitions that treat MMP as a multi-site disease rather than a sum of single-site responses. Until such criteria exist, clinicians managing multisite MMP should expect incomplete simultaneous remission, monitor oral and ocular mucosa closely after initial response, and weigh the relapse and adverse-event data when choosing between rituximab-based, JAK inhibitor and cyclophosphamide-based regimens.